NASDAQ:OPRX - OptimizeRx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.76 -0.75 (-6.52 %)
(As of 04/24/2019 04:00 PM ET)
Previous Close$11.51
Today's Range$10.28 - $11.71
52-Week Range$2.30 - $18.39
Volume52,710 shs
Average Volume47,950 shs
Market Capitalization$130.14 million
P/E Ratio215.20
Dividend YieldN/A
Beta1.03
OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It has a strategic partnership with Patient Connect to deliver real-time messaging at point-of-care in Europe. OptimizeRx Corporation is based in Rochester, Michigan.

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6568

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.21 million
Cash Flow$0.0637 per share
Book Value$1.54 per share

Profitability

Net Income$230,000.00

Miscellaneous

EmployeesN/A
Market Cap$130.14 million
Next Earnings Date5/1/2019 (Estimated)
OptionableNot Optionable

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Monday, November, 5th. The company reported $0.02 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.01. The firm earned $5.42 million during the quarter, compared to analyst estimates of $5.28 million. OptimizeRx had a net margin of 1.07% and a return on equity of 2.61%. View OptimizeRx's Earnings History.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for OptimizeRx.

What price target have analysts set for OPRX?

4 Wall Street analysts have issued 12-month price targets for OptimizeRx's shares. Their forecasts range from $17.00 to $25.00. On average, they expect OptimizeRx's share price to reach $20.00 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View Analyst Price Targets for OptimizeRx.

What is the consensus analysts' recommendation for OptimizeRx?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptimizeRx.

Has OptimizeRx been receiving favorable news coverage?

Media coverage about OPRX stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OptimizeRx earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include Micron Technology (MU), Amgen (AMGN), Inpixon (INPX), Conatus Pharmaceuticals (CNAT), Exelixis (EXEL), Harvard Bioscience (HBIO), Nuance Communications (NUAN), NVIDIA (NVDA), Sangamo Therapeutics (SGMO) and InterCloud Systems (ICLD).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the folowing people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (1.77%) and Tibra Equities Europe Ltd (0.22%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Institutional Ownership Trends for OptimizeRx.

Which institutional investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have sold OptimizeRx company stock in the last year include Awm Investment Company, Inc and Douglas P Baker. View Insider Buying and Selling for OptimizeRx.

Which institutional investors are buying OptimizeRx stock?

OPRX stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. Company insiders that have bought OptimizeRx stock in the last two years include Douglas P Baker, Ellen O'connor Vos, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Insider Buying and Selling for OptimizeRx.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $10.76.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $130.14 million and generates $21.21 million in revenue each year. The company earns $230,000.00 in net income (profit) each year or $0.05 on an earnings per share basis.

What is OptimizeRx's official website?

The official website for OptimizeRx is http://www.optimizerx.com.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]


MarketBeat Community Rating for OptimizeRx (NASDAQ OPRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about OptimizeRx and other stocks. Vote "Outperform" if you believe OPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: What is a conference call?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel